Research progress of immunotherapy in ovarian cancer

doi:10.19401/j.cnki.1007-3639.2020.07.009

China Oncology ›› 2020, Vol. 30 ›› Issue (7): 538-545.doi: 10.19401/j.cnki.1007-3639.2020.07.009

• Review • Previous Articles Next Articles

Research progress of immunotherapy in ovarian cancer

ZHAO Haiyun, WU Xiaohua

Department of Gynecology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Online:2020-07-30 Published:2020-08-06
Contact: WU Xiaohua E-mail: wu.xh@fudan.edu.cn

Abstract

Abstract: Five-year survival of ovarian cancer is 30%-45% for its non-obvious clinical symptoms, limited screening methods and advanced stage at initial diagnosis, which seriously threatens the health of women. Immunotherapy, especially immune checkpoint blockade, has been approved for treatment for patients with metastatic or recurrent multiple cancers for its durable anti-tumor effect. Also, the research progress of immunotherapy provides clinical management of ovarian cancer patients with new opportunities and challenges.

Key words: Ovarian cancer, Immunotherapy, Immune checkpoint blockade

ZHAO Haiyun, WU Xiaohua. Research progress of immunotherapy in ovarian cancer[J]. China Oncology, 2020, 30(7): 538-545.

[1]	LEI Yajie , GAO Yi , WANG Zhijie , CHENG Xi , YANG Yufei , ZHOU Hongyu , CHEN Lihua , CHEN Yixin , LI Haoran , LI Ziting , WU Xiaohua . Potential role of lymphadenectomy in patients with ovarian cancer (ⅠC-ⅡA): a retrospective trial [J]. China Oncology, 2021, 31(8): 740-745.
[2]	XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia. The advances in immunotherapy biomarkers of small cell lung cancer [J]. China Oncology, 2021, 31(7): 635-639.
[3]	ZHU Jun, WU Xiaohua. Leading research progress and prospect of gynecological oncology in 2020 [J]. China Oncology, 2021, 31(4): 250-256.
[4]	CAI Shumo, TANG Jie, HUANG Xiao, HUANG Xiaowei, LIU Suping, KE Guihao, ZHENG Zhong, CHENG Xi, TANG Meiqin. Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases [J]. China Oncology, 2021, 31(4): 330-334.
[5]	LIU Yixuan , WEN Zexuan , GUO Lin , LU Renquan . The function of TTK1 in platinum-resistant ovarian cancer [J]. China Oncology, 2021, 31(3): 182-191.
[6]	YU Yi, CONG Qing, XU Congjian, JIANG Wei. The effect of PAFR on cisplatin sensitivity in ovarian cancer cells and its mechanism [J]. China Oncology, 2021, 31(11): 1063-1071.
[7]	WANG Zhihen , MAO Peimin , JIANG Hongyuan , FAN Lingling . Assessment of the diagnostic value of CPH-I, CA12-5 and HE4 for cancer prediction in women with ovarian masses with papillary projections diagnosed by ultrasound [J]. China Oncology, 2020, 30(8): 599-604.
[8]	WANG Xiaoqin, FU Xinlei, MA Ruyue, YANG Lina, CHEN Yaping, ZHANG Liwen. Sema3A regulates metastasis through epithelial-mesenchymal transition/matrix metalloproteinase-2 in epithelial ovarian cancer [J]. China Oncology, 2020, 30(6): 428-434.
[9]	FENG Zheng, WU Xiaohua. Hematological toxicities of maintenance PARP inhibitors for patients with platinum-sensitive recurrent ovarian cancer [J]. China Oncology, 2020, 30(4): 299-304.
[10]	ZHU Xiaodong, CHEN Siyuan. Combination therapy of immune checkpoint inhibitors: from rationale to practice [J]. China Oncology, 2020, 30(12): 969-976.
[11]	XU Wencai, GUO Leiming, CUI Yingying, LIU Xiao, JIANG Yue, GE Hong. The effect of lung stereotactic body radiotherapy on peripheral blood lymphocytes [J]. China Oncology, 2020, 30(12): 1013-1016.
[12]	LI Guoyu , HE Ming . New progress in the research of immunotherapy for extensive-stage small cell lung cancer [J]. China Oncology, 2020, 30(10): 826-833.
[13]	PAN Zeyan, ZHAN Xianbao. Current status and future strategies of chimeric antigen receptor T-cells in the treatment of pancreatic cancer [J]. China Oncology, 2019, 29(7): 481-485.
[14]	WU Xiaohua, ZHANG Jian, YIN Rutie, LOU Ge, GAO Yunong. Chinese expert experience in optimizing stage Ⅰ clinical study management of ovarian cancer [J]. China Oncology, 2019, 29(5): 321-327.
[15]	PAN Yingying, ZHOU Fei, ZHOU Caicun. The perspects and challenges of immunotherapy for lung cancer [J]. China Oncology, 2019, 29(4): 241-249.

Research progress of immunotherapy in ovarian cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments